Avacopan (Tavneos): where things stand
Facts and dates only, checked against FDA, EMA, the journal record, Amgen and the Vasculitis Foundation.
Every medical claim on this page links to its source. Last updated 15 November 2026. Educational information, not medical advice.
Do not stop or change any medicine without talking to your prescriber. FDA and Amgen both advise patients to talk with their prescriber.1,2
Where things stand on 15 Nov 2026
- United States: still FDA-approved and available while FDA considers a proposal to withdraw approval. No final FDA decision found.1,2
- European Union: marketing authorisation revoked by a European Commission decision on 4 August 2026.3
Timeline
| Date | Event |
|---|---|
| 16 Jan 2026 | FDA requested a voluntary withdrawal from the U.S. market (as reported by the Vasculitis Foundation).4 |
| 31 Mar 2026 | FDA Drug Safety Communication on serious drug-induced liver injury, including vanishing bile duct syndrome. FDA identified 76 cases with reasonable evidence of a causal link; 74 were serious, including 8 deaths.5 |
| 27 Apr 2026 | FDA's Center for Drug Evaluation and Research proposed withdrawing approval, stating the drug has not been shown to be effective and that the application contained untrue statements of material fact (docket FDA-2026-N-1321).1 |
| 25 Jun 2026 | EMA's CHMP recommended revoking the EU authorisation: no new patients; patients on treatment to be switched; liver monitoring.3 |
| 29 Jun 2026 | The New England Journal of Medicine retracted the 2021 ADVOCATE trial paper.6 |
| 23 Jul 2026 | Amgen submitted additional data supporting its request for an FDA hearing.2 |
| 4 Aug 2026 | European Commission issued its final, legally binding decision revoking the EU authorisation.3 |
| 24 Sep 2026 | The Vasculitis Foundation requested a public hearing with FDA.4 |
| 3 Nov 2026 | Amgen's third-quarter report: "We continue to engage with the U.S. Food and Drug Administration (FDA) and believe that TAVNEOS demonstrates clinical effectiveness and a favorable benefit-risk profile."7 |
| 20 Nov 2026 | Vasculitis Foundation virtual listening session for the community (scheduled).4 |
Two positions, stated neutrally
FDA's drug center and EMA concluded that the evidence no longer supports the drug's benefit. Amgen disagrees and has said an independent re-adjudication of the trial (company-reported) supports effectiveness; it has requested a hearing.1,3,2
Questions to ask your prescriber
- Does this affect my current treatment plan?
- What liver tests do I need, and how often?
- What symptoms of liver problems should I report (for example yellow skin or eyes, itching, dark urine)?5
Sources
- U.S. FDA: CDER proposes to withdraw approval of TAVNEOS [doc ref 18]
- Amgen: TAVNEOS update (company statement and FAQ)
- European Medicines Agency: Tavneos: Article 20 referral (CHMP opinion and European Commission final decision) [doc ref 20]
- Vasculitis Foundation: TAVNEOS (avacopan) update for the vasculitis community
- U.S. FDA: Drug Safety Communication: serious liver injury in patients taking Tavneos (avacopan) [doc ref 18]
- PubMed record of NEJM notice (29 Jun 2026): Retraction: Jayne DRW et al. Avacopan for the treatment of ANCA-associated vasculitis (ADVOCATE) [doc ref 19]
- Amgen via SEC EDGAR: Amgen third-quarter 2026 earnings release (filed 3 Nov 2026) [doc ref 21]
Links checked 15 November 2026. Full list: all sources.